

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Asthma management

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Scope: before consultation (To be completed by the developer and submitted with the draft scope for consultation)

1.1 Have any potential equality issues been identified during the development of the draft scope, before consultation, and, if so, what are they?

(Please specify if the issue has been highlighted by a stakeholder)

Specific consideration will be given to the needs of children and pregnant women.

Differing outcomes associated with different ethnic groups (e.g. South Asian family origin) and people with learning disabilities will be considered.

Consideration will be given with regards to self-management plans and patient information for those people who have sight, reading or language barriers.

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

None of the 8 protected groupings is excluded.

Optimal management of children is likely to differ from that of adults. The range of licensed medications differs slightly, and the best management options at any stage of severity may not be the same. Recommendations for children are therefore likely to be different than those for adults.

Optimal management of asthma in pregnancy may differ from that of non-pregnant people with asthma. There is evidence of worse outcomes of asthma during pregnancy, although this is probably because women sometimes stop taking medication when pregnant rather than because of any intrinsic change in the asthma. The GDG will consider this when appraising evidence.

There is some evidence that outcomes from asthma are worse in those of South Asian ethnic origin, and the developers will consider whether this merits any management recommendations specific to this group.

2.0 Scope: after consultation (To be completed by the developer and submitted with the final scope)

2.1 Have any potential equality issues been identified during consultation, and, if so, what are they?

One stakeholder commented that consideration should be made with regards to written asthma action plans and patient information for those people who have sight, reading or language barriers.

2.2 Have any changes to the scope been made as a result of consultation to highlight potential equality issues?

No changes to the scope have been made but the committee will take these highlighted issues into consideration when drafting recommendations.

2.3 Is the primary focus of the guideline a population with a specific disability-related communication need?

If so, is an alternative version of the 'Information for the Public' document recommended?

If so, which alternative version is recommended?

The alternative versions available are:

- large font or audio versions for a population with sight loss;
- British Sign Language videos for a population who are deaf from birth;
- 'Easy read' versions for people with learning disabilities or cognitive impairment.

No

3.0 Guideline development: before consultation (to be completed by the developer before draft guideline consultation)

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

3.3 Were the Committee's considerations of equality issues described in the consultation document, and, if so, where?

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

Completed by Developer _____

Date _____

Completed by Committee Chair _____

Date _____

Approved by NICE quality assurance lead

Date _____

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.2, 4.3 and 4.4, or otherwise fulfil NICE's obligations to advance equality?

4.5 Have the Committee's considerations of equality issues been described in the final guideline document, and, if so, where?

Updated by Developer _____

Date _____

Updated by Committee Chair _____

Date _____

Approved by NICE quality assurance lead

Date _____

5.0 After Guidance Executive amendments – if applicable (To be completed by appropriate NICE staff member after Guidance Executive)

5.1 Outline amendments agreed by Guidance Executive below, if applicable:

--

Approved by Developer _____

Date _____

Approved by Committee Chair _____

Date _____

Approved by NICE quality assurance lead

Date _____